Logo

BCDA

BioCardia, Inc.

BCDA

BioCardia, Inc. • NASDAQ
$1.42 ▼ -1.05% (-0.01)
Market Cap $8.21 M
52w High $3.20
52w Low $1.00
Dividend Yield 0%
P/E -1
Volume 94
Outstanding Shares 5.80M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.381M ▲ $-1.483M ▲ 0% $-236.23 ▼ $-1.376M ▲
Q2-2025 $0 $683K ▼ $-2.049M ▲ 0% $-0.4 ▲ $-2.046M ▲
Q1-2025 $0 $1.196M ▲ $-2.712M ▼ 0% $-0.99 ▼ $-2.714M ▼
Q4-2024 $0 $906K ▼ $-2.296M ▼ 0% $-0.84 ▼ $-2.306M ▼
Q3-2024 $0 $1.648M $-1.737M 0% $-0.61 $-1.629M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.287M ▲ $6.148M ▲ $3.521M ▼ $2.627M ▲
Q2-2025 $980K ▲ $2.089M ▼ $3.975M ▲ $-1.886M ▼
Q1-2025 $949K ▼ $2.166M ▼ $3.686M ▲ $-1.52M ▼
Q4-2024 $2.371M ▼ $3.724M ▼ $2.887M ▼ $837K ▼
Q3-2024 $4.93M $6.267M $3.514M $2.753M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.483M ▲ $-1.672M ▼ $0 ▲ $5.979M ▲ $4.307M ▲ $-1.672M ▼
Q2-2025 $-2.049M ▲ $-1.649M ▼ $-1K ▼ $1.681M ▲ $31K ▲ $-1.65M ▼
Q1-2025 $-2.712M ▼ $-1.618M ▲ $0 ▲ $196K ▲ $-1.422M ▲ $-1.618M ▲
Q4-2024 $-2.296M ▼ $-2.573M ▲ $-1K ▲ $15K ▼ $-2.559M ▼ $-2.574M ▲
Q3-2024 $-1.737M $-2.611M $-2K $6.122M $3.509M $-2.613M

Revenue by Products

Product Q4-2022Q1-2023Q2-2023Q3-2023
Collaboration Agreement
Collaboration Agreement
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement BioCardia is essentially a pre‑revenue company. Over the past several years it has not generated meaningful sales and has run at a steady operating loss. Losses have been fairly consistent year after year, reflecting ongoing research and clinical spending without any offsetting product revenue yet. Earnings per share have looked very weak, but that is heavily distorted by repeated reverse stock splits rather than a sudden change in the underlying business. Overall, this is a classic clinical‑stage biotech income statement: costs and losses now in hopes of future approvals and commercialization.

Balance Sheet

Balance Sheet The balance sheet is very light. The company holds only a small base of assets, mostly cash, and carries no notable debt, which reduces financial leverage risk but also highlights how limited its resources are. Equity has gradually eroded as losses accumulated, leaving only a thin capital cushion. This profile suggests a company that depends heavily on external funding to keep operating and to advance its pipeline. Any delay or setback in raising capital or in clinical progress could put financial pressure on the organization.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing spending on research, clinical trials, and overhead without incoming product cash. Capital spending is minimal, so most cash use is tied directly to running and advancing the programs rather than to heavy equipment or facilities. Free cash flow has been negative for years, which is normal for an early‑stage biotech but underscores that the business is not self‑funding and will likely need continued access to capital markets, partnerships, or grants to sustain operations.

Competitive Edge

Competitive Edge BioCardia is trying to differentiate itself in a crowded cardiovascular space by combining three elements: personalized cell therapy, off‑the‑shelf cell therapy, and a specialized delivery system. Its proprietary Helix catheter and associated tools give it a potential edge in precisely delivering therapies to the heart, and its FDA Breakthrough Device designation for the CardiAMP platform adds regulatory visibility. The dual strategy of both patient‑specific and donor‑based therapies broadens its potential reach compared with single‑focus peers. However, competition is intense, with larger and better‑funded players in cell therapy and heart failure, and BioCardia’s small scale and limited financial resources are important constraints on its competitive strength.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of BioCardia. The company has built a technology stack around three main platforms: CardiAMP (using a patient’s own cells with a built‑in screening assay to select likely responders), CardiALLO (donor‑derived, off‑the‑shelf cells for broader and faster use), and the Helix delivery system that aims to place cells safely and accurately into heart tissue. These are backed by a patent portfolio and a strategy to possibly use Helix as a platform for other companies’ biologic therapies. Additional work on advanced imaging (Heart3D fusion imaging) points to a desire to refine procedure precision. The upside is a differentiated, integrated solution; the key risk is execution: proving clinical benefit in pivotal trials, navigating regulators, and securing partners, all while managing tight finances.

Summary

BioCardia is a tiny, clinically focused biotech with promising but unproven technology and almost no current commercial footprint. Financially, it is pre‑revenue, loss‑making, and reliant on external capital, with a very slim asset and equity base but no meaningful debt. Strategically, its strength lies in an integrated approach to cardiac regenerative medicine that combines personalized and off‑the‑shelf cell therapies with a proprietary delivery platform and imaging tools, supported by regulatory recognition and patents. The main uncertainties center on clinical trial outcomes, regulatory approvals, partnership traction, and the company’s ability to fund itself through to potential commercialization. For anyone following the company, the story is less about current financial performance and more about whether its scientific and regulatory milestones can be achieved before financial constraints become too tight.

NEWS

November 24, 2025 · 8:15 AM UTC

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Read more

November 12, 2025 · 4:40 PM UTC

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

Read more

November 5, 2025 · 7:29 PM UTC

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

Read more

October 2, 2025 · 8:00 AM UTC

BioCardia Regains Compliance with Nasdaq Listing Requirements

Read more

September 18, 2025 · 9:15 AM UTC

BioCardia Announces Pricing of Up To $12 Million Public Offering

Read more